

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 2003/086320 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 45/00**,  
38/38, 38/19, C07K 1/00, 2/00, C12N 5/00, 5/06

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/US2003/008456

(22) International Filing Date: 27 March 2003 (27.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/370,936 8 April 2002 (08.04.2002) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JASKUNAS, Stanley, Richard** [US/US]; 4150 Juniper Court, Indianapolis, IN 46250 (US). **LI, De-Shan** [US/US]; 6317 Feather Run Drive, Indianapolis, IN 46237 (US). **LIU, Ling** [CA/US]; 10740 Putnam Place, Carmel, IN 46032 (US). **ZENG, Wei** [CA/US]; 5698 Aquamarine Drive, Carmel, IN 46033 (US).

(74) Agents: **PLANT, Thomas, G. et al.**; Eli Lilly And Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

## Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

## Published:

— with international search report

(88) Date of publication of the international search report:  
1 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF RESISTIN TO TREAT HEMATOPOIETIC DISORDERS

(57) Abstract: The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one resistin agonist, resistin polynucleotide and/or resistin polypeptide for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

WO 2003/086320 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/08456

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 45/00; A61K 38/38, 38/19; C07K 1/00, 2/00; C12N 5/00, 5/06  
 US CL : 424/85.1, 198.1; 435/4, 325, 375, 377; 530/300, 350, 351, 399; 514/2, 12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 424/85.1, 198.1; 435/4, 325, 375, 377; 530/300, 350, 351, 399; 514/2, 12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 6,503,730 B1 (FRANZ-BACON et al) 07 January 2003 (07.01.2003), col 27-28, SEQ ID NO: 2.	1, 4-6, 9, 11-13, 15
Y	STEPPAN et al. The hormone resistin links obesity to diabetes. Nature 409: 307-312 18 January 2001; see especially pages 307-308, Figure 2d.	1, 4-6, 9, 11-13, 15
Y.	Genbank Accession No. Q9HD89, 16 October 2001 (16.10.2001)	1, 4-6, 9, 11-13, 15
A, P	US 2002/0161210 A1 (LAZAR , M.) 31 October 2002 (31.10.2002)	1-15
A	HOLCOMB et al , A novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19(15): 4046-4055, 2000; Figure 2b, hFIZZ3	1-15
A	WO 99/55868 A2 ( GENENTECH, INC.) 04 November 1999 (04.11.1999), Figure 26, SEQ ID NO: 24	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 September 2003 (25.09.2003)

Date of mailing of the international search report

08 DEC 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

BrIDGET E. Bunner

Telephone No. (703) 308-0196

*Donna Collins Jr.*

INTERNATIONAL SEARCH REPORT

PCT/US03/08456

**Continuation of B. FIELDS SEARCHED Item 3:**  
EAST, DIALOG, MEDLINE, PGPUBS  
inventors' names, FIZZ, RELM, resistin, hematopoietic